

DEC 20 2005

K052779

>>Summary of Safety & Effectiveness

510(k) Summary as required by section 807.92(c)

Date: 01/16/05

Submission Applicant:
Bredent - Products for the
dental technician laboratory
Weissenhornerstr. 2
89250 Senden

Phone: xx49-7309-872-230
Fax: xx49-7309-872-24
E-mail: info@bredent.com

Establishment Registration Number:
1000303432

Application correspondent/Contact person:
think - healthcare management
Schwarzwaldstr. 11
D-78532 Tuttlingen/Germany

Phone: xx49-7462-91300
Fax: xx49-7462-91301
E-mail: denk@denkgruppe.de

Trade name:
Bredent - Bre.comp

Common name:
Tooth shade resin material

Classification name:
Tooth shade resin material, Dental (21 CFR 872.3690 - EBF)

Substantial Equivalence Claim:
K790439 - Vivadent (USA) Inc.

Description of the Device:

Bre.comp dentine/enamel/transparent is a light curing microhybride composite for anterior and posterior restorations. Bre.comp is based on BIS-GMA resins and inorganic fillers with particle size of 0.05 to 0.09 μm . The total filler content is 81% (weight percent) and 63% (volume percent). The composite material complies with the requirements of DIN EN ISO 4049

Application range:

Universal dental restorative material for the following indications:

- cavity classes I to V
- inlays, veneers (direct and indirect)
- crown suprastructures
- post and core buildups

>>Summary of Safety & Effectiveness

Indications for Use:

Bre.comp is intended to restore carious lesions or structural defects in teeth

Comparison with P.D.

The Bredent product is similar to the P.D. in terms of technical characteristics, design, Indications for Use, Target population, where it is used, performance, biocompatibility characteristics as well as sizes and configurations. **Therefore the Bredent product can be deemed substantially equivalent and safe and effective for its indicated use.**

Summary

The presented data that was conducted on the Bredent products shows in its results and in comparison to the predicate devices that the products are absolutely safe and effective for their intended use and do not raise any questions regarding safety and effectiveness. All models that are covered by this 510(k) premarket notification have been on the market in Europe for many years with no device failures. The used materials are well researched and do not raise any kind of question regarding safety and effectiveness of the finished product.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DEC 20 2005

Bredent
C/O Mr. Markus Denk
Think – Healthcare Management
Schwarzwaldstr. 11
D-78532 Tuttlingen
GERMANY

Re: K052779
Trade/Device Name: Brecomp
Regulation Number: 21 CFR 872.3690
Regulation Name: Tooth Shade Resin Material
Regulatory Class: II
Product Code: EBF
Dated: November 09, 2005
Received: November 16, 2005

Dear Mr. Denk:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu S. Lin, PhD

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

K 052779

Indications for Use

510(k) Number (if known): K 052779

Device Name: Brecomp

Indications For Use: Brecomp is intended to restore carious lesions or structural defects in teeth.

Prescription Use ☒
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Evan Quares

Special Agent in Charge, General Hospital,
Central Dental Devices

K 052779

06

Page 1 of _____